Literature DB >> 17961033

Intracranial meningiomas: an overview of diagnosis and treatment.

Jason Rockhill1, Maciej Mrugala, Marc C Chamberlain.   

Abstract

Meningiomas are extraaxial central nervous system tumors most often discovered in middle to late adult life, and are more often seen in women. Ninety percent of meningiomas are benign, 6% are atypical, and 2% are malignant. Most patients in whom a meningioma is diagnosed undergo resection to relieve neurological symptoms. Complete resection is often curative. For the majority of incompletely resected or recurrent tumors not previously irradiated, radiotherapy is administered. Radiotherapy may be administered as either conventional external-beam radiation therapy or stereotactically by linear accelerator, Leksell Gamma Knife, or Cyberknife radiosurgery. Advocates of stereo-tactic radiotherapy have suggested this therapy in lieu of surgery particularly in high-risk patients, those with meningiomas in eloquent or surgically inaccessible locations, and elderly patients. When the meningioma is unresectable or all other treatments (surgery and radiotherapy) have failed, hormonal therapy or chemotherapy may be considered. Notwithstanding limited data, hydroxyurea has been modestly successful in patients with recurrent meningiomas.

Entities:  

Mesh:

Year:  2007        PMID: 17961033     DOI: 10.3171/FOC-07/10/E1

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  47 in total

Review 1.  Update on meningiomas.

Authors:  Santosh Saraf; Bridget J McCarthy; J Lee Villano
Journal:  Oncologist       Date:  2011-10-25

2.  Demographic profile of patients diagnosed with intracranial meningiomas in two academic hospitals in Johannesburg, South Africa: a 12-month prospective study.

Authors:  Kaunda Ibebuike; John Ouma
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

Review 3.  "Dazed and diffused": making sense of diffusion abnormalities in neurologic pathologies.

Authors:  K M O'Connor; G Barest; T Moritani; O Sakai; A Mian
Journal:  Br J Radiol       Date:  2013-10-28       Impact factor: 3.039

4.  Identification of epithelial membrane protein 2 (EMP2) as a molecular marker and correlate for angiogenesis in meningioma.

Authors:  Kunal S Patel; Sameer Kejriwal; Michel M Sun; Samasuk Thammachantha; Courtney Duong; Ann Chan; Nina Cherian; Prasanth Romiyo; Lynn K Gordon; William Yong; Madhuri Wadehra; Isaac Yang
Journal:  J Neurooncol       Date:  2020-01-24       Impact factor: 4.130

5.  Improving Forward Infusion Pressure during Brain Tumor Embolization with the Double Catheter and Coil Technique.

Authors:  Sam Dayawansa; Sneha Konda; Walter S Lesley; Patrick T Noonan; Jason H Huang
Journal:  Neurointervention       Date:  2017-09-05

6.  Evaluation of the applicability of territorial arterial spin labeling in meningiomas for presurgical assessments compared with 3-dimensional time-of-flight magnetic resonance angiography.

Authors:  Yiping Lu; Shihai Luan; Li Liu; Ji Xiong; Jianbo Wen; Jianxun Qu; Daoying Geng; Bo Yin
Journal:  Eur Radiol       Date:  2017-03-16       Impact factor: 5.315

7.  Cavernous sinus syndrome: need for early diagnosis.

Authors:  Jaime Toro; Lisseth Estefania Burbano; Saúl Reyes; Paula Barreras
Journal:  BMJ Case Rep       Date:  2015-03-27

8.  Intraosseous schwannoma of the petrous apex.

Authors:  Christopher Goiney; Rita Bhatia; Kevin Auerbach; Michael Norenberg; Jacques Morcos
Journal:  J Radiol Case Rep       Date:  2011-11-01

Review 9.  Contemporary endovascular embolotherapy for meningioma.

Authors:  Gregory J Dubel; Sun Ho Ahn; Gregory M Soares
Journal:  Semin Intervent Radiol       Date:  2013-09       Impact factor: 1.513

10.  A microcosting study of microsurgery, LINAC radiosurgery, and gamma knife radiosurgery in meningioma patients.

Authors:  Siok Swan Tan; Erik van Putten; Wideke M Nijdam; Patrick Hanssens; Guus N Beute; Peter J Nowak; Clemens M Dirven; Leona Hakkaart-van Roijen
Journal:  J Neurooncol       Date:  2010-06-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.